We are live on ! Find out more
BMRN icon

BioMarin Pharmaceuticals

306 hedge funds and large institutions have $9.95B invested in BioMarin Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 51 funds opening new positions, 101 increasing their positions, 115 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more call options, than puts

Call options by funds: $94.9M | Put options by funds: $58.2M

31% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 39

4% more funds holding

Funds holding: 294306 (+12)

2% less capital invested

Capital invested by funds: $10.1B → $9.95B (-$167M)

12% less repeat investments, than reductions

Existing positions increased: 101 | Existing positions reduced: 115

22% less funds holding in top 10

Funds holding in top 10: 97 (-2)

Holders
306
Holders Change
+12
Holders Change %
+4.08%
% of All Funds
8.88%
Holding in Top 10
7
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-22.22%
% of All Funds
0.2%
New
51
Increased
101
Reduced
115
Closed
39
Calls
$94.9M
Puts
$58.2M
Net Calls
+$36.7M
Net Calls Change
+$3.33M
Name Holding Trade Value Shares
Change
Change in
Stake
MPA
326
Marvin & Palmer Associates
Delaware
-$1.12M -15,500 Closed
FCBT
327
First Citizens Bank & Trust
North Carolina
-$945K -13,095 Closed
KIA
328
Kopp Investment Advisors
Minnesota
-$844K -11,691 Closed
CCM
329
Cai Capital Management
New York
-$806K -11,163 Closed
HI
330
HBK Investments
Texas
-$621K -8,600 Closed
Verition Fund Management
331
Verition Fund Management
Connecticut
-$500K -6,928 Closed
Baillie Gifford & Co
332
Baillie Gifford & Co
United Kingdom
-$430K -5,949 Closed
RCM
333
Reynolds Capital Management
Nevada
-$368K -5,100 Closed
SGH
334
Schonfeld Group Holdings
New York
-$303K -4,200 Closed
TC
335
TFS Capital
Pennsylvania
-$271K -3,754 Closed
B
336
Barings
North Carolina
-$231K -3,200 Closed
GCT
337
Galaxy Capital Trading
British Virgin Islands
-$217K -3,000 Closed
NCCM
338
Nine Chapters Capital Management
New Jersey
-$217K -3,000 Closed
Teacher Retirement System of Texas
339
Teacher Retirement System of Texas
Texas
-$164K -2,270 Closed
CCMH
340
Cornerstone Capital Management Holdings
New York
-$75K -1,047 Closed
PC
341
Pier Capital
Connecticut
-$52K -720 Closed
MUMSS
342
Mitsubishi UFJ Morgan Stanley Securities
Japan
-$50K -690 Closed
PAS
343
Partnervest Advisory Services
California
-$20K -275 Closed
FNBT
344
FineMark National Bank & Trust
Florida
-$16K -219 Closed
WA
345
WealthTrust-Arizona
Arizona
-$1K -7 Closed

BMRN Hedge Fund Activity: Q4 2013 in Review

306 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q4 2013, worth a combined $9.95B — down 1.7% from $10.1B a quarter earlier.

Buyers outnumbered sellers: 51 funds opened new BMRN positions and 39 closed out — a net gain of 12 holders — while 101 added to existing stakes and 115 trimmed.

The largest buyer was Wells Fargo, adding an estimated $97.2M. The largest seller was Fidelity Investments, cutting an estimated $265M.

  • 306 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q4 2013, up from 294 in Q3 2013.
  • Funds reported $9.95B of BioMarin Pharmaceuticals stock for Q4 2013, down 1.7% quarter-over-quarter.
  • 51 funds opened new BioMarin Pharmaceuticals positions in Q4 2013 and 39 closed out, a net change of +12 holders.
  • The largest BioMarin Pharmaceuticals buyer in Q4 2013 was Wells Fargo, an estimated $97.2M added.
  • The largest BioMarin Pharmaceuticals seller in Q4 2013 was Fidelity Investments, an estimated $265M sold.

Based on aggregated 13F filings for Q4 2013.